Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Sell
31
SPRO Quote, Financials, Valuation and Earnings
Last price:
$2.28
Seasonality move
:
17.06%
Day range:
$2.24 - $2.33
52-week range:
$0.51 - $3.22
Dividend yield:
0%
P/E ratio:
10.75x
P/S ratio:
4.32x
P/B ratio:
4.85x
Volume:
241.7K
Avg. volume:
471.4K
1-year change:
93.22%
Market cap:
$128.5M
Revenue:
$27.4M
EPS (TTM):
-$0.79
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
SPRO
Spero Therapeutics, Inc.
|
-- | -$0.32 | -100% | -3.03% | $4.00 |
|
DARE
Daré Bioscience, Inc.
|
-- | -$0.40 | 2911.81% | -13.48% | $10.75 |
|
GOVX
GeoVax Labs, Inc.
|
-- | -- | -100% | -- | $9.63 |
|
HYPD
Hyperion DeFi, Inc.
|
-- | -- | -- | -- | -- |
|
OMER
Omeros Corp.
|
-- | -$0.48 | -- | -0.15% | $28.00 |
|
VTGN
Vistagen Therapeutics, Inc.
|
$145.8K | -$0.44 | -6.58% | -18.27% | $14.50 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
SPRO
Spero Therapeutics, Inc.
|
$2.28 | $4.00 | $128.5M | 10.75x | $0.00 | 0% | 4.32x |
|
DARE
Daré Bioscience, Inc.
|
$1.79 | $10.75 | $25.6M | 95.38x | $0.00 | 0% | 361.34x |
|
GOVX
GeoVax Labs, Inc.
|
$0.38 | $9.63 | $11.4M | -- | $0.00 | 0% | 1.66x |
|
HYPD
Hyperion DeFi, Inc.
|
$3.97 | -- | $32.1M | -- | $0.00 | 0% | 102.90x |
|
OMER
Omeros Corp.
|
$11.03 | $28.00 | $782M | -- | $0.00 | 0% | -- |
|
VTGN
Vistagen Therapeutics, Inc.
|
$4.28 | $14.50 | $169M | -- | $0.00 | 0% | 150.22x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
SPRO
Spero Therapeutics, Inc.
|
11.23% | 12.710 | 3.17% | 3.63x |
|
DARE
Daré Bioscience, Inc.
|
74.07% | 0.176 | 27.91% | 1.09x |
|
GOVX
GeoVax Labs, Inc.
|
-- | 1.075 | -- | 2.75x |
|
HYPD
Hyperion DeFi, Inc.
|
10.72% | 19.509 | 13.53% | 2.04x |
|
OMER
Omeros Corp.
|
254.22% | -1.203 | 126.5% | 0.76x |
|
VTGN
Vistagen Therapeutics, Inc.
|
2.73% | 0.724 | 1.35% | 5.66x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
SPRO
Spero Therapeutics, Inc.
|
-- | -$9.7M | -97.58% | -107.04% | -319% | $17.4M |
|
DARE
Daré Bioscience, Inc.
|
-$610.6K | -$3.7M | -459.12% | -- | -159660.87% | -$616.8K |
|
GOVX
GeoVax Labs, Inc.
|
-$16.8K | -$6.4M | -433.69% | -433.69% | -635.8% | -$6.2M |
|
HYPD
Hyperion DeFi, Inc.
|
$302.5K | -$2.7M | -90.16% | -143.24% | -881.16% | -$2.8M |
|
OMER
Omeros Corp.
|
-$240K | -$26.4M | -59.56% | -- | -- | -$18.5M |
|
VTGN
Vistagen Therapeutics, Inc.
|
$73K | -$20.1M | -74.76% | -76.57% | -7772.48% | -$13.8M |
Spero Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns SPRO or DARE?
Daré Bioscience, Inc. has a net margin of -242.19% compared to Spero Therapeutics, Inc.'s net margin of -154904.35%. Spero Therapeutics, Inc.'s return on equity of -107.04% beat Daré Bioscience, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SPROSpero Therapeutics, Inc.-- -$0.13 $29.8M DAREDaré Bioscience, Inc.-26547.83% -$0.28 $11M -
What do Analysts Say About SPRO or DARE?
Spero Therapeutics, Inc. has a consensus price target of $4.00, signalling upside risk potential of 75.44%. On the other hand Daré Bioscience, Inc. has an analysts' consensus of $10.75 which suggests that it could grow by 500.56%. Given that Daré Bioscience, Inc. has higher upside potential than Spero Therapeutics, Inc., analysts believe Daré Bioscience, Inc. is more attractive than Spero Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SPROSpero Therapeutics, Inc.0 2 0 DAREDaré Bioscience, Inc.3 0 0 -
Is SPRO or DARE More Risky?
Spero Therapeutics, Inc. has a beta of 1.482, which suggesting that the stock is 48.19% more volatile than S&P 500. In comparison Daré Bioscience, Inc. has a beta of 0.771, suggesting its less volatile than the S&P 500 by 22.917%.
-
Which is a Better Dividend Stock SPRO or DARE?
Spero Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Daré Bioscience, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Spero Therapeutics, Inc. pays -- of its earnings as a dividend. Daré Bioscience, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SPRO or DARE?
Spero Therapeutics, Inc. quarterly revenues are $3M, which are larger than Daré Bioscience, Inc. quarterly revenues of $2.3K. Spero Therapeutics, Inc.'s net income of -$7.4M is lower than Daré Bioscience, Inc.'s net income of -$3.6M. Notably, Spero Therapeutics, Inc.'s price-to-earnings ratio is 10.75x while Daré Bioscience, Inc.'s PE ratio is 95.38x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Spero Therapeutics, Inc. is 4.32x versus 361.34x for Daré Bioscience, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SPROSpero Therapeutics, Inc.4.32x 10.75x $3M -$7.4M DAREDaré Bioscience, Inc.361.34x 95.38x $2.3K -$3.6M
-
Which has Higher Returns SPRO or GOVX?
GeoVax Labs, Inc. has a net margin of -242.19% compared to Spero Therapeutics, Inc.'s net margin of -630.04%. Spero Therapeutics, Inc.'s return on equity of -107.04% beat GeoVax Labs, Inc.'s return on equity of -433.69%.
Company Gross Margin Earnings Per Share Invested Capital SPROSpero Therapeutics, Inc.-- -$0.13 $29.8M GOVXGeoVax Labs, Inc.-- -$0.31 $4.9M -
What do Analysts Say About SPRO or GOVX?
Spero Therapeutics, Inc. has a consensus price target of $4.00, signalling upside risk potential of 75.44%. On the other hand GeoVax Labs, Inc. has an analysts' consensus of $9.63 which suggests that it could grow by 2409.12%. Given that GeoVax Labs, Inc. has higher upside potential than Spero Therapeutics, Inc., analysts believe GeoVax Labs, Inc. is more attractive than Spero Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SPROSpero Therapeutics, Inc.0 2 0 GOVXGeoVax Labs, Inc.4 0 0 -
Is SPRO or GOVX More Risky?
Spero Therapeutics, Inc. has a beta of 1.482, which suggesting that the stock is 48.19% more volatile than S&P 500. In comparison GeoVax Labs, Inc. has a beta of 3.638, suggesting its more volatile than the S&P 500 by 263.848%.
-
Which is a Better Dividend Stock SPRO or GOVX?
Spero Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. GeoVax Labs, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Spero Therapeutics, Inc. pays -- of its earnings as a dividend. GeoVax Labs, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SPRO or GOVX?
Spero Therapeutics, Inc. quarterly revenues are $3M, which are larger than GeoVax Labs, Inc. quarterly revenues of --. Spero Therapeutics, Inc.'s net income of -$7.4M is lower than GeoVax Labs, Inc.'s net income of -$6.3M. Notably, Spero Therapeutics, Inc.'s price-to-earnings ratio is 10.75x while GeoVax Labs, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Spero Therapeutics, Inc. is 4.32x versus 1.66x for GeoVax Labs, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SPROSpero Therapeutics, Inc.4.32x 10.75x $3M -$7.4M GOVXGeoVax Labs, Inc.1.66x -- -- -$6.3M
-
Which has Higher Returns SPRO or HYPD?
Hyperion DeFi, Inc. has a net margin of -242.19% compared to Spero Therapeutics, Inc.'s net margin of --. Spero Therapeutics, Inc.'s return on equity of -107.04% beat Hyperion DeFi, Inc.'s return on equity of -143.24%.
Company Gross Margin Earnings Per Share Invested Capital SPROSpero Therapeutics, Inc.-- -$0.13 $29.8M HYPDHyperion DeFi, Inc.-- $0.05 $79.2M -
What do Analysts Say About SPRO or HYPD?
Spero Therapeutics, Inc. has a consensus price target of $4.00, signalling upside risk potential of 75.44%. On the other hand Hyperion DeFi, Inc. has an analysts' consensus of -- which suggests that it could fall by -49.62%. Given that Spero Therapeutics, Inc. has higher upside potential than Hyperion DeFi, Inc., analysts believe Spero Therapeutics, Inc. is more attractive than Hyperion DeFi, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SPROSpero Therapeutics, Inc.0 2 0 HYPDHyperion DeFi, Inc.0 0 0 -
Is SPRO or HYPD More Risky?
Spero Therapeutics, Inc. has a beta of 1.482, which suggesting that the stock is 48.19% more volatile than S&P 500. In comparison Hyperion DeFi, Inc. has a beta of 2.805, suggesting its more volatile than the S&P 500 by 180.539%.
-
Which is a Better Dividend Stock SPRO or HYPD?
Spero Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Hyperion DeFi, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Spero Therapeutics, Inc. pays -- of its earnings as a dividend. Hyperion DeFi, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SPRO or HYPD?
Spero Therapeutics, Inc. quarterly revenues are $3M, which are larger than Hyperion DeFi, Inc. quarterly revenues of $302.5K. Spero Therapeutics, Inc.'s net income of -$7.4M is lower than Hyperion DeFi, Inc.'s net income of $6.6M. Notably, Spero Therapeutics, Inc.'s price-to-earnings ratio is 10.75x while Hyperion DeFi, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Spero Therapeutics, Inc. is 4.32x versus 102.90x for Hyperion DeFi, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SPROSpero Therapeutics, Inc.4.32x 10.75x $3M -$7.4M HYPDHyperion DeFi, Inc.102.90x -- $302.5K $6.6M
-
Which has Higher Returns SPRO or OMER?
Omeros Corp. has a net margin of -242.19% compared to Spero Therapeutics, Inc.'s net margin of --. Spero Therapeutics, Inc.'s return on equity of -107.04% beat Omeros Corp.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SPROSpero Therapeutics, Inc.-- -$0.13 $29.8M OMEROmeros Corp.-- -$0.47 $143M -
What do Analysts Say About SPRO or OMER?
Spero Therapeutics, Inc. has a consensus price target of $4.00, signalling upside risk potential of 75.44%. On the other hand Omeros Corp. has an analysts' consensus of $28.00 which suggests that it could grow by 153.85%. Given that Omeros Corp. has higher upside potential than Spero Therapeutics, Inc., analysts believe Omeros Corp. is more attractive than Spero Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SPROSpero Therapeutics, Inc.0 2 0 OMEROmeros Corp.2 2 0 -
Is SPRO or OMER More Risky?
Spero Therapeutics, Inc. has a beta of 1.482, which suggesting that the stock is 48.19% more volatile than S&P 500. In comparison Omeros Corp. has a beta of 2.485, suggesting its more volatile than the S&P 500 by 148.518%.
-
Which is a Better Dividend Stock SPRO or OMER?
Spero Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Omeros Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Spero Therapeutics, Inc. pays -- of its earnings as a dividend. Omeros Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SPRO or OMER?
Spero Therapeutics, Inc. quarterly revenues are $3M, which are larger than Omeros Corp. quarterly revenues of --. Spero Therapeutics, Inc.'s net income of -$7.4M is higher than Omeros Corp.'s net income of -$21.2M. Notably, Spero Therapeutics, Inc.'s price-to-earnings ratio is 10.75x while Omeros Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Spero Therapeutics, Inc. is 4.32x versus -- for Omeros Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SPROSpero Therapeutics, Inc.4.32x 10.75x $3M -$7.4M OMEROmeros Corp.-- -- -- -$21.2M
-
Which has Higher Returns SPRO or VTGN?
Vistagen Therapeutics, Inc. has a net margin of -242.19% compared to Spero Therapeutics, Inc.'s net margin of -7525.97%. Spero Therapeutics, Inc.'s return on equity of -107.04% beat Vistagen Therapeutics, Inc.'s return on equity of -76.57%.
Company Gross Margin Earnings Per Share Invested Capital SPROSpero Therapeutics, Inc.-- -$0.13 $29.8M VTGNVistagen Therapeutics, Inc.28.3% -$0.54 $68.2M -
What do Analysts Say About SPRO or VTGN?
Spero Therapeutics, Inc. has a consensus price target of $4.00, signalling upside risk potential of 75.44%. On the other hand Vistagen Therapeutics, Inc. has an analysts' consensus of $14.50 which suggests that it could grow by 238.79%. Given that Vistagen Therapeutics, Inc. has higher upside potential than Spero Therapeutics, Inc., analysts believe Vistagen Therapeutics, Inc. is more attractive than Spero Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SPROSpero Therapeutics, Inc.0 2 0 VTGNVistagen Therapeutics, Inc.4 0 0 -
Is SPRO or VTGN More Risky?
Spero Therapeutics, Inc. has a beta of 1.482, which suggesting that the stock is 48.19% more volatile than S&P 500. In comparison Vistagen Therapeutics, Inc. has a beta of 0.561, suggesting its less volatile than the S&P 500 by 43.86%.
-
Which is a Better Dividend Stock SPRO or VTGN?
Spero Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vistagen Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Spero Therapeutics, Inc. pays -- of its earnings as a dividend. Vistagen Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SPRO or VTGN?
Spero Therapeutics, Inc. quarterly revenues are $3M, which are larger than Vistagen Therapeutics, Inc. quarterly revenues of $258K. Spero Therapeutics, Inc.'s net income of -$7.4M is higher than Vistagen Therapeutics, Inc.'s net income of -$19.4M. Notably, Spero Therapeutics, Inc.'s price-to-earnings ratio is 10.75x while Vistagen Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Spero Therapeutics, Inc. is 4.32x versus 150.22x for Vistagen Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SPROSpero Therapeutics, Inc.4.32x 10.75x $3M -$7.4M VTGNVistagen Therapeutics, Inc.150.22x -- $258K -$19.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 62x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 38x
Buy
63
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 40x
Alerts
Buy
54
SMX alert for Dec 5
SMX (Security Matters) Plc [SMX] is up 154.74% over the past day.
Sell
15
HOV alert for Dec 5
Hovnanian Enterprises, Inc. [HOV] is down 22.58% over the past day.
Buy
67
NUTX alert for Dec 5
Nutex Health, Inc. [NUTX] is up 18.9% over the past day.
